Page last updated: 2024-09-03

gefitinib and thalidomide

gefitinib has been researched along with thalidomide in 11 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(thalidomide)
Trials
(thalidomide)
Recent Studies (post-2010) (thalidomide)
5,2315662,9199,7891,3854,342

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)thalidomide (IC50)
Cereblon isoform 4Magnetospirillum gryphiswaldense7.8
Prostaglandin G/H synthase 1Ovis aries (sheep)0.37
Prostaglandin G/H synthase 2Ovis aries (sheep)0.5
DNA damage-binding protein 1Homo sapiens (human)1.38
Protein cereblonHomo sapiens (human)1.38

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cooney, MM; Remick, SC; Vogelzang, NJ1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H1
Chon, HS; Hu, W; Kavanagh, JJ1
Curtiss, FR1
Dhalluin, X; Scherpereel, A1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES1
Chaplain, MAJ; Hill, L; Kapelyukh, Y; Wolf, R1
Guo, Z; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X; Zhang, F1

Reviews

5 review(s) available for gefitinib and thalidomide

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Novel agents for the treatment of advanced kidney cancer.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide

2004
Targeted therapies in gynecologic cancers.
    Current cancer drug targets, 2006, Volume: 6, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Transfer Techniques; Genital Neoplasms, Female; Humans; Neovascularization, Pathologic; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thalidomide; Thionucleotides; Trastuzumab

2006
Chemotherapy and radiotherapy for mesothelioma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 189

    Topics: Antineoplastic Agents; Asbestos; Combined Modality Therapy; Gefitinib; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mesothelioma; Pleural Neoplasms; Quinazolines; Ribonucleases; Thalidomide

2011
Novel molecular targeted therapies for refractory thyroid cancer.
    Head & neck, 2012, Volume: 34, Issue:5

    Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat

2012

Other Studies

6 other study(ies) available for gefitinib and thalidomide

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
[Molecular-targeted therapy for hormone-refractory prostate cancer].
    Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6

    Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D

2006
Pharmacy benefit spending on oral chemotherapy drugs.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States

2006
The usage of a three-compartment model to investigate the metabolic differences between hepatic reductase null and wild-type mice.
    Mathematical medicine and biology : a journal of the IMA, 2017, 03-01, Volume: 34, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Cytochrome P-450 Enzyme System; Disease Models, Animal; GABA Modulators; Gefitinib; Liver; Mice; Mice, Transgenic; Midazolam; Models, Biological; NADPH-Ferrihemoprotein Reductase; Protein Kinase Inhibitors; Quinazolines; Thalidomide

2017
Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    European journal of pharmacology, 2019, Aug-05, Volume: 856

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Intracellular Space; Lung Neoplasms; Neoplasm Invasiveness; Protein Kinase Inhibitors; Signal Transduction; Thalidomide

2019